The Effects of Calcitriol on Biomarkers in Diabetic Kidney Disease Patients
Diabetic Kidney Disease
About this trial
This is an interventional treatment trial for Diabetic Kidney Disease focused on measuring Diabetic Kidney Disease, Podocin, Nephrin, Calcitriol, Tubular injury, Podocyte injury
Eligibility Criteria
Inclusion Criteria:
- Controlled type 2 diabetes mellitus with HbA1C at least <8% and albuminuria (UACR>30 mg/mmol)
- Estimated Glomerular Filtration Rate (eGFR) >45 ml/min/1.73 m2
- Agree to participate in the research
Exclusion Criteria:
- Uncontrolled hypertension with routine Angiotensin-converting-enzyme inhibitors (ACEi) or Angiotensin II receptor blockers (ARBs) treatment
- Hypercalcemia (total serum Ca level >10/5 mg/dL)
- Hyperphosphatemia (total serum phosphate level >5 mg/dL)
- Hypersensitivity to calcitriol
- Suffering from other diseases that cause proteinuria
- Acute diseases
- Smoker or previous smoking history
- Taking medications or suplements that can affect calcitriol metabolism (thiazide, digoxin, anti-convulsant)
Sites / Locations
- Dr. Cipto Mangunkusumo Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Intervention Group
Placebo Group
Drug: Calcitriol The intervention group will be given calcitriol at a dose of 0.25 mcg/day for six months in the form of capsules that have been marked and numbered. The drugs will be taken through the RSCM pharmacy once a month during visit and the allocation will be given using drug labels that are sealed and packaged identically.
Drug: Placebo oral The placebo drug will be given for six months in the form of capsules that have been marked and numbered. The drugs will be taken through the RSCM pharmacy once a month during visit and the allocation will be given using drug labels that are sealed and packaged identically.